Ceritinib： From Synthesis to Clinical Applications  

作　　者：Xiuyan Cui Weihua Song Qi Yang Zhangqun Yang 

机构地区：[1]Department of Pharmacy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China

出　　处：《Journal of Pharmacy and Pharmacology》2016年第8期390-393,共4页药剂与药理学（英文版）

摘　　要：Lung cancer is the major cause of cancer-related mortality, accountingfor over one quarter of cancer deaths. Lung cancers are generally divided into two main categories： SCLC （small cell lung cancer） and NSCLC （non-small cell lung cancer）. NSCLC accounts for approximately 85% of all lung cancers. ALK （anaplastic largecell kinase） gene rearrangements are identified and targeted resulting in promising response rates for NSCLC in early studies. Ceritinib is a second-generation ALK inhibitor that has demonstrated activity in crizotinib （the first-generation ALK inhibitor）-resistant patients. In this paper, the synthesis, pharmacodynamics, pharmacokinetics, therapeutic trials, adverse events and drug-drug interactions are briefly overviewed in order to make more scholars, medical workers and patients have a more clear and comprehensive recognition on this drug.

关 键 词：Ceritinib non-small cell lung cancer ALK inhibitor review. 

分 类 号：S852.43[农业科学—基础兽医学] S859.796[农业科学—兽医学]